Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

Antzeko izenburuak

• Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
  nork: Laure Gossec, et al.
  Argitaratua: (2024-02-01)
• Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
  nork: Coates, LC, et al.
  Argitaratua: (2024)
• Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
  nork: Coates, L, et al.
  Argitaratua: (2022)
• Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free
  nork: Coates, LC, et al.
  Argitaratua: (2021)
• The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria
  nork: Ritchlin, CT, et al.
  Argitaratua: (2023)